Aptahem AB (publ)

Stockholm Stock Exchange APTA.ST

Aptahem AB (publ) Capital Expenditure for the year ending December 31, 2023: USD -1.04 M

Aptahem AB (publ) Capital Expenditure is USD -1.04 M for the year ending December 31, 2023, a 76.77% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • Aptahem AB (publ) Capital Expenditure for the year ending December 31, 2022 was USD -4.48 M, a -8,397.62% change year over year.
  • Aptahem AB (publ) Capital Expenditure for the year ending December 31, 2021 was USD -52.74 K, a 18.80% change year over year.
  • Aptahem AB (publ) Capital Expenditure for the year ending December 31, 2020 was USD -64.95 K, a -259.53% change year over year.
  • Aptahem AB (publ) Capital Expenditure for the year ending December 31, 2019 was USD -18.06 K, a 0.00% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Stockholm Stock Exchange: APTA.ST

Aptahem AB (publ)

CEO Mr. Mikael Lindstam
IPO Date April 17, 2015
Location Sweden
Headquarters Norra Vallgatan 58, 4TR
Employees 5
Sector Health Care
Industries
Pharmaceuticals Biotechnology Clinical Trials
Description

Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children's Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.

StockViz Staff

January 15, 2025

Any question? Send us an email